Compare VanEck Gold Miners ETF (GDX) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Novavax Inc — how do they compare? VanEck Gold Miners ETF trades at $89.28 (market cap $25.65B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: VanEck Gold Miners ETF is far larger — about 14.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Novavax Inc for 59 Days on average.
| GDX | NVAX | |
|---|---|---|
Market Cap | $25.65B | $1.82B |
Volume | 16,534,046 | 6,198,505 |
52-Week High | $115.84 | $12.56 |
52-Week Low | $68.28 | $6.22 |
Typical Hold Time | 76 Days | 59 Days |
Sector | — | Health |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $89.28, up 4.47% over 24 hours but remains in a bearish technical trend with key resistance at $89. The fund provides exposure to gold mining equities, though specific financial ratios are not available in the provided data. Recent news highlights institutional selling and comparisons between gold miners and physical gold investments.
The outlook for GDX is mixed, with technical indicators signaling caution but potential for gains if gold prices rise. Risks include sensitivity to gold prices, interest rate changes, and miner operational issues. Opportunities exist if macroeconomic factors boost gold demand, but volatility is a key concern for investors.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
